Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof.

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof.

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state:

##STR00001##

Also provided are processes of manufacture and methods of using the crystalline forms.

The invention is directed to a method for recovering carboyxlic acid from an magnesium carboxylate containing aqueous mixture, including the steps of: contacting the aqueous mixture with an acidic ion exchanger, thereby forming a carboxylic acid mixture and an ion exchanger loaded with magnesium ions; contacting the ion exchanger loaded with magnesium ions with a hydrochloric acid solution, thereby forming a magnesium chloride solution; and thermally decomposing the magnesium chloride solution at a temperature of at least 300 C., thereby forming magnesium oxide (MgO) and hydrogen chloride (HCl).

The invention is directed to a method for recovering carboyxlic acid from an magnesium carboxylate containing aqueous mixture, including the steps of: contacting the aqueous mixture with an acidic ion exchanger, thereby forming a carboxylic acid mixture and an ion exchanger loaded with magnesium ions; contacting the ion exchanger loaded with magnesium ions with a hydrochloric acid solution, thereby forming a magnesium chloride solution; and thermally decomposing the magnesium chloride solution at a temperature of at least 300 C., thereby forming magnesium oxide (MgO) and hydrogen chloride (HCl).

The invention relates to new and improved processes for the preparation of Indacaterol and pharmaceutically acceptable salts thereof as well as intermediates for the preparation of Indacaterol. The new process avoids the use of the epoxide compound known in the art and the impurities associated therewith and results in a higher yield.

The invention relates to new and improved processes for the preparation of Indacaterol and pharmaceutically acceptable salts thereof as well as intermediates for the preparation of Indacaterol. The new process avoids the use of the epoxide compound known in the art and the impurities associated therewith and results in a higher yield.

Disclosed are a crystal form of a RIPK1 inhibitor, an acid salt thereof, and a crystal form of an acid salt thereof. The crystal form of the RIPK1 inhibitor, the acid salt thereof, and the crystal form of the acid salt thereof have advantages of good stability and low hygroscopicity, and same have good pharmaceutical prospects.

##STR00001##